Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristian Angeby"'
Publikováno v:
International Journal of Mycobacteriology, Vol 1, Iss 4, Pp 177-179 (2012)
Introduction: New drugs against multi-(MDR) and extensively drug (XDR) resistant tuberculosis are urgently needed. While new candidate drugs are being developed, reinvestigation of already approved drugs available for other indications could be of va
Externí odkaz:
https://doaj.org/article/a04728a613884d829fe98692c7495206
Autor:
Alvar Grönberg, Louise Zettergren, Kerstin Bergh, Mona Ståhle, Johan Heilborn, Kristian Angeby, Pamela L Small, Hannah Akuffo, Sven Britton
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13839 (2010)
BACKGROUND: Mycobacterium ulcerans is the causative agent of necrotizing skin ulcerations in distinctive geographical areas. M. ulcerans produces a macrolide toxin, mycolactone, which has been identified as an important virulence factor in ulcer form
Externí odkaz:
https://doaj.org/article/3ad7ff5c29ab4cc3aecda03f5859777a
Autor:
Erja, Chryssanthou, Kristian, Angeby
Publikováno v:
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 120(5)
The performance of the GenoType(®) MTBDRplus assay was compared with conventional drug susceptibility testing (DST) in 604 patients with tuberculosis. The study comprised 477 Mycobacterium tuberculosis complex isolates and 127 preparations of DNA fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fa70833c986af07adbc4016a83bf269
https://pubmed.ncbi.nlm.nih.gov/22515295
https://pubmed.ncbi.nlm.nih.gov/22515295
Autor:
Anandi Martin, Stefan Panaiotov, Françoise Portaels, Sven Hoffner, Juan Carlos Palomino, Kristian Angeby
Publikováno v:
Journal of Antimicrobial Chemotherapy (JAC); Jul2008, Vol. 62 Issue 1, p56-56, 1p